Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva Faces Laquinimod Setback After High Dose Linked To CV Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva will discontinue higher doses of laqunimod in two ongoing studies for multiple sclerosis after cardiovascular events were experienced in eight patients. Trials will continue with a lower dose.


Related Content

Teva Stumbles, Actelion Rises In MS: Clinical Protocols Lost And Gained
Teva Pins Long-Term Hopes In MS On The Return Of Laquinimod
Disappointing BRAVO Data Raise Doubts About Laquinimod's Chances With FDA
No Homerun, But A Base Hit For Teva's Laquinimod


Related Companies

Related Deals